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antiplatelet therapy, inpatient and outpatient treatment of
ischemic stroke, MI, and bleeds, and long-term care for
patients with disability. We examined the cost-effective-
ness of clopidogrel for subgroups of patients deﬁned on
the basis of age at therapy initiation (55, 65, and 75 years)
and gender. Cost-effectiveness was assessed using the
ratio of the difference (clopidogrel minus aspirin) in
expected lifetime medical-care costs to the corresponding
difference in life expectancy. A 3% discount rate was
used. RESULTS: One hundred patients with recent IS,
recent MI, or PAD receiving clopidogrel would experience
4.5–6.3 fewer atherothrombotic events and 3.6–8.7 
fewer bleeds over their lifetimes in comparison with 100
patients receiving aspirin. The expected gain in life-years
ranges from 0.33–0.69 per patient. Expected total life-
time medical-care costs are $9,222–$16,850 higher for 
clopidogrel patients. Cost-effectiveness of clopidogrel
ranges from $40,204–$49,107 per life-year saved, and is
sensitive to the assumed risk reduction for clopidogrel.
CONCLUSION: Clopidogrel is cost-effective versus
aspirin in patients with recent IS, recent MI, or PAD.
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OBJECTIVE: This retrospective, observational, health
plan administrative claims database study examined
treatment patterns, resource utilization, and costs of
venous thromboembolic (VTE) disease [deep venous
thrombosis (DVT) and pulmonary embolism (PE)] in a
managed care setting. METHODS: Medical and phar-
macy claims of patients with a newly diagnosed VTE
event were gathered from 2 US health plan databases
from January 1997 through September 2001. Inclusion
criteria included a VTE event between January 1, 1998
and December 31, 2000 (no VTE diagnosis or anti-
coagulation therapy 3 months prior to index VTE event),
continuous health plan enrollment 6 months prior and 12
months after index VTE event, and a VTE medication ﬁll
after index date. Medical and pharmacy care associated
with recurrent VTE or bleeding events were based on each
patient’s index VTE event, and detailed by type, number,
and cost. Costs of recurrent episodes were calculated
using general linear model regression and bootstrap tech-
niques. RESULTS: A total of 2147 patients (DVT = 1499;
PE = 373; DVT&PE = 275) were enrolled (mean age =
61.6 ± 15.9 years, 46.3% male). Median pre- and post-
index observation times were 17.1 and 19.2 months,
respectively. Mean total medical costs for DVT, PE, and
DVT&PE during the index VTE episode were $2293,
$7157, and $3963, respectively. Warfarin treatment was
administered for a mean 6.3 months at an average cost
of $145. The annualized rates and adjusted costs of post-
index VTE events were 9.48% and $5331, respectively,
for VTE episodes; and 5.52% and $8978, respectively, 
for bleeding episodes. The rate of recurrent VTE episodes
was signiﬁcantly lower in the DVT group than in the PE
group, and the cost of post-index bleed episodes was 
signiﬁcantly higher in the PE group. No other recurrent
rates or cost differences were signiﬁcant. CONCLU-
SIONS: Current therapy for VTE patients is associated
with high costs and signiﬁcant recurrent and adverse
events. Approaches to therapy that increase effectiveness
and decrease risk are needed.
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Gender variation in diagnosis and treatment of ADHD is
well documented: boys are more likely to be diagnosed
and receive pharmacologic treatment than girls. However,
little is known about gender variation in the quality
(dosage and persistence) of pharmacologic treatment
received by ADHD-diagnosed children. OBJECTIVE: To
examine gender variation in intensity and persistence of
psychostimulant treatment among a national, population-
based sample of ADHD-diagnosed children. METHODS:
We analyzed medical and pharmaceutical claims in the
Medical Expenditures Panel Survey (MEPS) from January
1 through December 31, 1998 among all ADHD-diag-
nosed children (N = 195) aged 4–19 years. Psychostimu-
lant doses were converted to Methylphenidate Equivalent
Units (MEU) according to previously published research
(MEU: 20mg Methylphenidate = 10mg dextroampheta-
mine = 10mg amphetamine salts = 56.25mg Pemoline).
Doses were classiﬁed as high (>15.0mg MEU), medium
(5.0–15.0mg MEU), or low (<5.0mg MEU). Persistence
of treatment was determined by number of prescription
ﬁlls (PF) in a calendar year. Separate weighted logistic and
multiple regression analyses were conducted with MEU
and PF as dependent variables respectively. RESULTS: As
has been reported previously in the literature, males were
1.3 (+/-0.004) times more likely to receive a prescription
for psychostimulants (p < 0.001). However, among 
those receiving any psychostimulant, females were 1.2
(+/-0.008) times more likely than males to receive high
doses (p < 0.001). There was no difference in persistence
of psychostimulant treatment by gender. CONCLUSION:
Whereas girls with AD/HD were less likely to be treated
with psychostimulants, once treated, they received higher
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doses. Further research is required to conﬁrm whether
such gender disparities persist, and, if so, whether they
are justiﬁed. Additional research linking quality with 
outcomes of care are necessary to determine their effects
on the outcomes of children with ADHD. In this way,
researchers and clinicians can work together to translate
ﬁndings into better patient care.
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THE RELATIONSHIP OF ASTHMA AND
GENERALIZED ANXIETY DISORDER 
IN ADULTS
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OBJECTIVE: To determine the association between
asthma and generalized anxiety disorder for adults utiliz-
ing a PBM. METHODS: Adult participants (age 18–65
years) were retrospectively identiﬁed in Caremark’s PBM
database and assessed for asthma and generalized anxiety
disorder (GAD) from January 2002–September 2002.
Using pharmacy algorithms, asthmatic participants and
non-asthmatic participants were identiﬁed and compared
as having GAD where anxiety medication supply
exceeded 27 days. Sub-analysis of the asthma popula-
tion compared the utilization of speciﬁc drug classes to
the association of anxiety disorder. All populations were
compared using odds ratio analysis. RESULTS: A total 
of 4,238,840 participants (58.5% female) were evaluated
over the study period; 205,964 (4.86%) were identiﬁed
as being asthmatic (60.2% female, mean age 51.5 years,
std 15.7 years); 210,972 (4.98%) of the study population
were being treated with anti-anxiety medications; and
16,912 (0.4%) of the participants were treated with both.
Asthma was associated with a signiﬁcant increased 
likelihood of anxiety disorder (OR: 1.77; 95% CI: 1.74
to 1.80). Treatment with steroid inhalants and/or
leukotriene modulators was associated with a signiﬁcant
decrease in the likelihood of anxiety disorders among
asthmatics (OR: 0.89; 95% CI: 0.87 to 0.92). While treat-
ment with asthma combination medications was associ-
ated with a higher signiﬁcant increased likelihood of GAD
among asthmatics (OR: 2.22; 95% CI: 1.72 to 2.86).
CONCLUSION: These ﬁndings are consistent with pre-
viously published self-reported data showing an associa-
tion between asthma and GAD. In this study, participants
treated for asthma were found to be 77% more likely to
be treated for GAD than the general non-asthmatic 
population. Participants using steroid inhalants or
leukotriene modulators were 11% less likely to be treated
for GAD than other asthmatics. The use of asthma 
combination therapy was associated with 120%
increased likelihood of GAD treatment, possibly indicat-
ing the severity of the asthma condition is correlated to
an increased likelihood of GAD. Increased attention
needs to be placed on the management of anxiety as a
comorbidity of asthma.
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OBJECTIVES: HEDIS guidelines recommend patients
with depression remain on antidepressant therapy for a
minimum of six months to receive full clinical beneﬁt.
This study compared differences in healthcare costs based
upon length of SSRI therapy. METHODS: Continuously
eligible patients >18 years of age receiving SSRI therapy
diagnosed as having depression in a managed Medicaid
program from July 1, 1999 to December 31, 2000 were
eligible for study inclusion. Length of therapy was deﬁned
as total SSRI days supply acquired within six months of
the index date. Patients were placed into the following
cohorts based upon length of therapy or drug utilization
patterns: 1) <90 days; 2) 90–179 days; 3) >180 days; or
4) Switched/Augmented (SA). Differences in pharmaceu-
tical, professional, hospital and total healthcare costs
were evaluated across the four cohorts over a 1-year
follow-up period. RESULTS: There were 2250 patients
meeting all inclusion criteria. Only 34% of patients
received >180 days of therapy. While 24% had <90 days
of therapy, 21% had 90–179 days and 21% had evidence
of switching/augmentation. Demographic and back-
ground covariates were similar across all cohorts. As
expected, pharmaceutical charges increased as length 
of therapy increased, being highest in the SA cohort.
However, as length of therapy increased from <90 days
to >180 days, professional services and hospital charges
decreased by an average of $816 annually per patient.
Total monthly healthcare costs in the >180 day cohort
remained stable after at least 6 months of SSRI treatment
through the full 12-months that patients were followed.
CONCLUSIONS: Pharmaceutical costs increased as SSRI
length of therapy improves. However, healthcare costs
decreased due to reductions in hospital and professional
service charges for patients maintained on SSRIs for at
least the recommended six months of continuous therapy.
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EXPERIENCE
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OBJECTIVE: There is little research describing the effects
of the introduction of generic ﬂuoxetine to the SSRI
market. The purpose of this analysis is to examine uti-
lization of the SSRI class in a Pennsylvania Medicaid
HMO before and after the launch of ﬂuoxetine (generic)
